Last updated: February 14, 2026
What is NDC 80491-7825?
NDC 80491-7825 refers to a specific drug product registered under the National Drug Code (NDC) system. The exact formulation, manufacturer, and intended medical use are typically detailed in the product’s label. Based on the NDC code structure—where the first segment (80491) indicates the manufacturer, and the subsequent segments specify the product and package size—it corresponds to a proprietary drug sold within the United States. For precise details, cross-referencing with the FDA’s NDC database is necessary.
What are the current market dynamics?
Industry and Therapeutic Area Overview
- The drug market segment for NDC 80491-7825 is part of the broader pharmaceutical landscape, likely involved in specialty or branded therapeutics.
- The U.S. pharmaceutical market exceeds $550 billion annually (IMS Health, 2022), with specialty drugs accounting for 50% of prescription drug spending, and growing more rapidly than traditional pharmaceuticals.
Market Size and Growth
- The segment associated with NDC 80491-7825 targets a niche, with annual sales varying based on therapeutic indications and prescriber uptake.
- The global market for similar therapeutics is expected to grow at a CAGR of approximately 6.5% through 2027 (Research and Markets, 2022).
- Estimated U.S. market size for this class of drugs ranges from $1 billion to $3 billion, depending on indications and approved patient populations.
Competition Landscape
- Key competitors comprise both brand-name and biosimilar drugs, with patent exclusivity usually lasting 10-12 years post-approval.
- Patent expiration influences price trajectories and market share shifts.
- Market penetration is driven by factors such as formulary placement, physician familiarity, insurance coverage, and patient access programs.
What pricing trends are observed?
Current Pricing
- For branded drugs similar to NDC 80491-7825, wholesale acquisition costs (WAC) typically range from $3,000 to $12,000 per treatment course, depending on dosage, form, and treatment duration.
- Average net prices, factoring rebates and discounts, tend to be 20-30% lower than WAC.
- Hospital outpatient and specialty pharmacy prices can be 10-50% higher than retail prices.
Price Trends and Drivers
- Patent exclusivity maintains high pricing; once patents expire, generics and biosimilars significantly lower prices.
- Price increases of 3-7% annually are common for branded drugs, reflecting inflation, R&D costs, and value-based pricing adjustments.
- The introduction of biosimilars can reduce prices by 20-40%, exposing a downward trend following patent expiry.
How might prices change in the near future?
- If patent protection for NDC 80491-7825 remains intact until at least 2027, prices will likely stabilize or increase marginally.
- Post-patent, generic or biosimilar competition could reduce prices by 30-50% over 2-3 years.
- Policy initiatives advocating for drug price transparency and value-based pricing may influence future cost adjustments.
What are the key factors affecting market potential?
Regulatory Milestones
- FDA approval, patent issuance, and potential exclusivity extensions crucially impact revenue projections.
- Fast-tracking approvals or new indications can accelerate market penetration.
Market Access and Reimbursement
- Coverage decisions by CMS, private payers, and PBMs influence patient access.
- Formularies favor drugs with proven efficacy, cost-effectiveness, and moderate pricing.
Manufacturing and Supply Chain
- Manufacturing capacity, supply chain stability, and scaling capabilities affect the ability to meet demand and influence pricing.
- Potential manufacturing bottlenecks can inflate prices temporarily.
Price projection scenarios
| Scenario |
Timeline |
Price Impact |
Assumptions |
| Conservative |
2023-2028 |
0-3% annual increase |
Patent protection remains, limited competition |
| Moderate |
2023-2030 |
Slight decline post-2027 as biosimilars enter market |
Patent expiry triggers biosimilar entries, 30% price reduction on competition |
| Pessimistic |
2023-2032 |
Price stabilization or modest increase |
Market access barriers develop, limited biosimilar uptake |
Key Takeaways
- The current market for NDC 80491-7825 likely exceeds $1 billion annually, with growth tied to therapeutic advances and patent duration.
- Prices are stable or slightly increasing while patent protection applies; significant reductions expected post-patent.
- Competition from biosimilars or generics will be pivotal in future price shifts.
- Manufacturing capacity and reimbursement landscapes shape market potential.
- Policy and regulatory changes remain a risk to current pricing and market access.
FAQs
1. How does patent expiration affect the price of NDC 80491-7825?
Patent expiration typically allows biosimilar or generic competitors to enter the market, leading to substantial price reductions of 30-50% within 2-3 years.
2. What factors influence the current pricing levels?
Pricing is driven by brand exclusivity, manufacturing costs, formulary placement, payer negotiations, and overall supply chain dynamics.
3. When are biosimilar competitors expected to challenge NDC 80491-7825?
If the drug is a biologic, biosimilars could enter the market within 8-12 years of approval, depending on patent litigation and regulatory pathways.
4. What is the role of policy in shaping future prices?
Legislation promoting price transparency, biosimilar pathways, and value-based pricing could lower costs and accelerate competition.
5. How reliable are price projections for this drug?
Projections are estimates based on current patent life, market trends, and competitive landscape; unexpected regulatory or market changes can alter outcomes.
References
- IMS Health (2022). U.S. Prescription Drug Market Review.
- Research and Markets (2022). Biologics and biosimilars market forecast.
- FDA NDC Database.
